Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice

Chang,Ya-Jen; Yu,Chia-Yu; Hsu,Chin-Wei; Lee,Wan-Chi; Chen,Su-Jung; Chang,Chih-Hsien; Lee,Te-Wei

doi:10.3892/or.2012.1978

Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice

Authors:
- Ya-Jen Chang
- Chia-Yu Yu
- Chin-Wei Hsu
- Wan-Chi Lee
- Su-Jung Chen
- Chih-Hsien Chang
- Te-Wei Lee
View Affiliations

Affiliations: Institute of Nuclear Energy Research, No. 1000 Wenhua Rd., Jiaan Village, Longtan Township, Taoyuan County 32546, Taiwan, R.O.C.
Published online on: August 22, 2012 https://doi.org/10.3892/or.2012.1978
Pages: 1736-1742

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liposomes are good candidates as drug carriers and have been widely investigated in drug delivery systems. In this study, a new combination of bimodal 188Re-(DXR)-liposome-BBN radiochemotherapeutics was designed and studied for treating solid pancreatic tumor by intravenous administration. The in vivo nuclear microSPECT/CT imaging of tumor targeting, prolonged survival time and therapeutic efficacy were evaluated in AR42J malignant pancreatic solid tumor-bearing nude mice. MicroSPECT/CT imaging of 188Re-liposome-BBN pointed to significant targeting in tumors at 24 h after intravenous injection (SUV=2.13±0.98). Co-injection of a blocking dose of cold BBN (4 mg/kg) inhibited the accumulation of 188Re-liposome-BBN in tumors (SUV=1.82±0.31). For therapeutic efficacy, inhibition of tumor growth in mice treated with 188Re-DXR-liposome-BBN was precisely controlled [mean growth inhibition rate (MGI) = 0.092] and had longer survival time [life-span (LS) = 86.96%] than those treated with anticancer drug 188Re-liposome-BBN (MGI = 0.130; LS = 75%), Lipo-Dox-BBN (MGI = 0.666; LS = 3.61%) and untreated control mice. An additive tumor regression effect was observed (CI 0.946) for co-delivery of 188Re-DXR-liposome-BBN radiochemotherapeutics. These results point to the potential benefit of the 188Re-(DXR)-liposome-BBN radiochemotherapeutics for adjuvant cancer treatment with applications in oncology.

View Figures

View References

1	Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2:750–763. 2002. View Article : Google Scholar : PubMed/NCBI
2	Maison W and Frangioni JV: Improved chemical strategies for the targeted therapy of cancer. Angew Chem Int Ed Engl. 42:4726–4728. 2003. View Article : Google Scholar : PubMed/NCBI
3	Markwalder R and Reubi JC: Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59:1152–1159. 1999.PubMed/NCBI
4	Sun B, Halmos G, Schally AV, Wang X and Martinez M: Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 42:295–303. 2000. View Article : Google Scholar : PubMed/NCBI
5	Gugger M and Reubi JC: Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 155:2067–2076. 1999. View Article : Google Scholar : PubMed/NCBI
6	Halmos G, Wittliff JL and Schally AV: Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 55:280–287. 1995.PubMed/NCBI
7	Toi-Scott M, Jones CL and Kane MA: Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer. 15:341–354. 1996. View Article : Google Scholar : PubMed/NCBI
8	Minamino N, Kangawa K and Matsuo H: Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun. 114:541–548. 1983. View Article : Google Scholar : PubMed/NCBI
9	McDonald TJ, Jornvall H, Tatemoto K and Mutt V: Identification and characterization of variant forms of the gastrin-releasing peptide (GRP). FEBS Lett. 156:349–356. 1983. View Article : Google Scholar : PubMed/NCBI
10	Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 56:1649–1659. 2004. View Article : Google Scholar : PubMed/NCBI
11	Allen TM and Cullis PR: Drug delivery systems: entering the mainstream. Science. 303:1818–1822. 2004. View Article : Google Scholar : PubMed/NCBI
12	Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145–160. 2005. View Article : Google Scholar : PubMed/NCBI
13	Newman MS, Colbern GT, Working PK, Engbers C and Amantea MA: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 43:1–7. 1999. View Article : Google Scholar
14	Vaage J, Donovan D, Wipff E, et al: Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer. 80:134–137. 1999. View Article : Google Scholar
15	Chang YJ, Chang CH, Yu CY, et al: Therapeutic efficacy and microSPECT/CT imaging of ¹⁸⁸Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol. 37:95–104. 2010.PubMed/NCBI
16	Chen MH, Chang CH, Chang YJ, et al: MicroSPECT/CT imaging and pharmacokinetics of ¹⁸⁸Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res. 30:65–72. 2010.PubMed/NCBI
17	Emfietzoglou D, Kostarelos K and Sgouros G: An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med. 42:499–504. 2001.PubMed/NCBI
18	Ting G, Chang CH and Wang HE: Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res. 29:4107–4118. 2009.PubMed/NCBI
19	Ercan MT and Caglar M: Therapeutic radiopharmaceuticals. Curr Pharm Des. 6:1085–1121. 2000.PubMed/NCBI
20	Chang YJ, Chang CH, Chang TJ, et al: Biodistribution, pharmacokinetics and microSPECT/CT imaging of ¹⁸⁸Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res. 27:2217–2225. 2007.PubMed/NCBI
21	Carlsson G, Gullberg B and Hafstrom L: Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 105:20–23. 1983.PubMed/NCBI
22	Fang F, Wang AP and Yang SF: Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin. 26:1373–1381. 2005. View Article : Google Scholar : PubMed/NCBI
23	Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK and Lee HY: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 13:2795–2803. 2007. View Article : Google Scholar : PubMed/NCBI
24	Maddalena ME, Fox J, Chen J, et al: 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 50:2017–2024. 2009. View Article : Google Scholar : PubMed/NCBI
25	Tan Y, Sun X, Xu M, et al: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res. 5:2157–2163. 1999.PubMed/NCBI
26	Chen LC, Chang CH, Yu CY, et al: Biodistribution, pharmacokinetics and imaging of ¹⁸⁸Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol. 34:415–423. 2007.PubMed/NCBI
27	Iznaga-Escobar N: ¹⁸⁸Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Nucl Med Biol. 25:441–447. 1998. View Article : Google Scholar
28	O'Donoghue JA, Bardies M and Wheldon TE: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 36:1902–1909. 1995.PubMed/NCBI
29	Li G, Wang Y, Huang K, Zhang H, Peng W and Zhang C: The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of ¹⁸⁸Re-herceptin. Nucl Med Biol. 32:59–65. 2005. View Article : Google Scholar : PubMed/NCBI
30	Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ and Papahadjopoulos D: Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:6774–6781. 1992.PubMed/NCBI
31	Papahadjopoulos D, Allen TM, Gabizon A, et al: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 88:11460–11464. 1991. View Article : Google Scholar : PubMed/NCBI
32	Zhao H, Wang JC, Sun QS, Luo CL and Zhang Q: RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target. 17:10–18. 2009. View Article : Google Scholar : PubMed/NCBI
33	Xiong XB, Huang Y, Lu WL, et al: Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 107:262–275. 2005. View Article : Google Scholar
34	Xiong XB, Huang Y, Lu WL, et al: Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci. 94:1782–1793. 2005. View Article : Google Scholar : PubMed/NCBI
35	Meng S, Su B, Li W, et al: Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol. 28:1180–1187. 2011. View Article : Google Scholar : PubMed/NCBI
36	Wartchow CA, Alters SE, Garzone PD, et al: Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier. Pharm Res. 21:1880–1885. 2004. View Article : Google Scholar : PubMed/NCBI
37	Li L, Wartchow CA, Danthi SN, et al: A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated ⁹⁰Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 58:1215–1227. 2004. View Article : Google Scholar : PubMed/NCBI
38	Du H, Cui C, Wang L, Liu H and Cui G: Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations. Mol Pharm. 8:1224–1232
39	Turk MJ, Waters DJ and Low PS: Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213:165–172. 2004. View Article : Google Scholar : PubMed/NCBI
40	Milas L, Stephens LC and Meyn RE: Relation of apoptosis to cancer therapy. In Vivo. 8:665–673. 1994.PubMed/NCBI
41	Meyn RE, Stephens LC, Hunter NR and Milas L: Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs. 6:443–450. 1995. View Article : Google Scholar : PubMed/NCBI
42	Cunningham D: Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer. 32A(Suppl 3): S1–S8. 1996. View Article : Google Scholar : PubMed/NCBI
43	Chung KY and Saltz LB: Adjuvant therapy of colon cancer: current status and future directions. Cancer J. 13:192–197. 2007. View Article : Google Scholar : PubMed/NCBI
44	Chen LC, Chang CH, Yu CY, et al: Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of ¹⁸⁸Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol. 35:883–893. 2008. View Article : Google Scholar : PubMed/NCBI
45	Tsai CC, Chang CH, Chen LC, et al: Biodistribution and pharmacokinetics of ¹⁸⁸Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomed. 6:2607–2619. 2011.